Direct evidence for a phenotype shift, especially in tamoxifen-treated patients may be obtainable by comparing recurrent disease with the primary cancer or monitoring PgR status in peripheral blood as has been done for HER-2 (Meng et al, 2004). This evidence concerns the gene ERBB2 and cancer.